CR20120121A - Compuestos de benzoxazepina como inhibidores de la pi3k y métodos de uso - Google Patents
Compuestos de benzoxazepina como inhibidores de la pi3k y métodos de usoInfo
- Publication number
- CR20120121A CR20120121A CR20120121A CR20120121A CR20120121A CR 20120121 A CR20120121 A CR 20120121A CR 20120121 A CR20120121 A CR 20120121A CR 20120121 A CR20120121 A CR 20120121A CR 20120121 A CR20120121 A CR 20120121A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- pi3k inhibitors
- benzoxazepine compounds
- benzoxazepine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La invención se refiere a compuestos de benzoxazepina de la formula (I)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24638109P | 2009-09-28 | 2009-09-28 | |
US33068510P | 2010-05-03 | 2010-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20120121A true CR20120121A (es) | 2012-06-01 |
Family
ID=43037239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20120121A CR20120121A (es) | 2009-09-28 | 2012-03-13 | Compuestos de benzoxazepina como inhibidores de la pi3k y métodos de uso |
Country Status (32)
Country | Link |
---|---|
US (7) | US8242104B2 (es) |
EP (3) | EP2711368B1 (es) |
JP (2) | JP5540101B2 (es) |
KR (1) | KR101428346B1 (es) |
CN (2) | CN102762576B (es) |
AR (1) | AR078187A1 (es) |
AU (1) | AU2010299816C1 (es) |
BR (1) | BR112012006807A2 (es) |
CA (1) | CA2772691C (es) |
CL (1) | CL2012000754A1 (es) |
CO (1) | CO6491026A2 (es) |
CR (1) | CR20120121A (es) |
DK (1) | DK2483278T3 (es) |
EC (1) | ECSP12011755A (es) |
ES (2) | ES2570569T3 (es) |
HK (2) | HK1174629A1 (es) |
HR (1) | HRP20140229T1 (es) |
IL (2) | IL217558A (es) |
MA (1) | MA33531B1 (es) |
MX (1) | MX2012003591A (es) |
MY (2) | MY184074A (es) |
NZ (1) | NZ597833A (es) |
PE (1) | PE20121025A1 (es) |
PL (1) | PL2483278T3 (es) |
PT (1) | PT2483278E (es) |
RS (1) | RS53164B (es) |
RU (2) | RU2600927C2 (es) |
SG (1) | SG10201405049RA (es) |
SI (1) | SI2483278T1 (es) |
TW (1) | TWI423980B (es) |
WO (1) | WO2011036280A1 (es) |
ZA (1) | ZA201202199B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010276537B2 (en) | 2009-07-27 | 2015-04-16 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
KR101428346B1 (ko) * | 2009-09-28 | 2014-08-07 | 에프. 호프만-라 로슈 아게 | 벤즈옥사제핀 pi3k 억제 화합물 및 사용 방법 |
JP5546636B2 (ja) * | 2009-09-28 | 2014-07-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンゾキセピンpi3k阻害剤化合物及び使用方法 |
EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
BR112013024122A2 (pt) * | 2011-03-21 | 2019-09-24 | Hoffmann La Roche | compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso |
TWI510480B (zh) | 2011-05-10 | 2015-12-01 | Gilead Sciences Inc | 充當離子通道調節劑之稠合雜環化合物 |
WO2012156379A1 (en) | 2011-05-13 | 2012-11-22 | Universität Zürich | PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING |
TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
NO3175985T3 (es) * | 2011-07-01 | 2018-04-28 | ||
EP2814830A1 (en) | 2012-02-17 | 2014-12-24 | F.Hoffmann-La Roche Ag | Tricyclic compounds and methods of use therefor |
BR112014028376A2 (pt) * | 2012-06-08 | 2018-04-24 | Hoffmann La Roche | métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção |
AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
CN102775395A (zh) * | 2012-07-12 | 2012-11-14 | 江苏七洲绿色化工股份有限公司 | 一种丙环唑的制备方法及丙环唑中间体 |
US9303046B2 (en) * | 2012-08-07 | 2016-04-05 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
AU2014230812B2 (en) * | 2013-03-13 | 2016-04-07 | F. Hoffmann-La Roche Ag | Process for making benzoxazepin compounds |
JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 |
AU2014365079B2 (en) * | 2013-12-16 | 2017-07-06 | F. Hoffmann-La Roche Ag | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof |
WO2015136016A2 (en) | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
TW201636329A (zh) | 2015-02-02 | 2016-10-16 | 佛瑪治療公司 | 作為hdac抑制劑之雙環[4,6,0]異羥肟酸 |
US10112915B2 (en) | 2015-02-02 | 2018-10-30 | Forma Therapeutics, Inc. | 3-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors |
AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
CN107531721B (zh) * | 2015-04-30 | 2020-07-17 | 诺华股份有限公司 | 用于调节法尼醇x受体的稠合的三环吡唑衍生物 |
CA2981159A1 (en) | 2015-06-29 | 2017-01-05 | F. Hoffmann-La Roche Ag | Methods of treatment with taselisib |
EP3567045B1 (en) | 2015-07-02 | 2022-01-12 | F. Hoffmann-La Roche AG | Benzoxazepin oxazolidinone compounds and methods of use |
JP6522807B2 (ja) * | 2015-07-02 | 2019-05-29 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法 |
US10065970B2 (en) | 2015-09-08 | 2018-09-04 | Genentech, Inc. | Tricyclic PI3K inhibitor compounds and methods of use |
US9721369B2 (en) * | 2015-09-15 | 2017-08-01 | Facebook, Inc. | Systems and methods for utilizing multiple map portions from multiple map data sources |
US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
MX2019003714A (es) | 2016-09-29 | 2019-06-24 | Bayer Cropscience Ag | Novedosos derivados de imidazolilmetilo 5-sustituidos. |
AU2017378188B2 (en) * | 2016-12-15 | 2020-11-26 | F. Hoffmann-La Roche Ag | Process for the preparation of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide |
HUE064898T2 (hu) | 2017-03-02 | 2024-04-28 | Genentech Inc | HER2-pozitív emlõrák adjuváns kezelése |
TWI826373B (zh) * | 2017-04-28 | 2023-12-21 | 瑞士商赫孚孟拉羅股份公司 | (s)-2-((2-((s)-4-(二氟甲基)-2-氧代唑烷-3-基)-5,6-二氫苯并[f]咪唑并[1,2-d][1,4]氧氮呯-9-基)胺基)丙醯胺之多晶型及固體形式及製造方法 |
ES2947411T3 (es) * | 2017-10-26 | 2023-08-08 | Xynomic Pharmaceuticals Inc | Sales cristalinas de un campo inhibidor de quinasa B-RAF |
KR20210018304A (ko) * | 2018-05-30 | 2021-02-17 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 트리사이클릭 유도체를 함유하는 억제제, 이를 위한 제조 방법, 및 이의 적용 |
CN111909157B (zh) * | 2019-05-07 | 2023-02-03 | 南京药石科技股份有限公司 | Ezh2抑制剂及其用途 |
WO2021088845A1 (zh) * | 2019-11-04 | 2021-05-14 | 贝达药业股份有限公司 | 咪唑烷酮类化合物及其制备方法与应用 |
KR20220097466A (ko) * | 2019-11-04 | 2022-07-07 | 베타 파머수티컬 컴퍼니 리미티드 | 이미다졸리디논류 화합물 및 이들의 제조방법과 용도 |
AU2020389670A1 (en) * | 2019-11-25 | 2022-05-19 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof |
IL308459A (en) | 2021-05-13 | 2024-01-01 | Betta Pharmaceuticals Co Ltd | A polymorph of an imidazolidinone compound, its preparation method and use |
CN117377660A (zh) | 2021-05-28 | 2024-01-09 | 基因泰克公司 | 用于苯并氧氮杂䓬恶唑烷酮化合物的制备的方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
GB8504702D0 (en) | 1985-02-23 | 1985-03-27 | Zyma Sa | Tricyclic compounds |
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
FR2677356B1 (fr) | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
WO1994014777A1 (en) | 1992-12-28 | 1994-07-07 | Eisai Co., Ltd. | Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar) |
AU678503B2 (en) * | 1993-09-24 | 1997-05-29 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds and their use as squalene synthetase inhibitors |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
AU1272597A (en) | 1995-11-17 | 1997-06-11 | E.I. Du Pont De Nemours And Company | Tricyclic herbicidal heterocycles |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
DE19908533A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen |
DE19908537A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
DE19908538A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen |
DE19908535A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
US7273880B2 (en) | 1999-06-30 | 2007-09-25 | H. Lunbeck A/S | Selective NPY (Y5) antagonists |
AU2001246494A1 (en) | 2000-03-03 | 2001-09-12 | Novartis Ag | Condensed thiazolamines and their use as neuropeptide y5 antagonists |
JP2004529911A (ja) | 2001-02-02 | 2004-09-30 | シェーリング コーポレイション | Cxcケモカインレセプターアンタゴニストとしての3,4−二置換シクロブテン−1,2−ジオン |
TWI232863B (en) * | 2001-06-11 | 2005-05-21 | Akzo Nobel Nv | Benzoxazepine derivatives |
WO2004009582A1 (en) | 2002-07-19 | 2004-01-29 | Pharmacia Corporation | Substituted thiophene carboxamide compounds for the treatment of inflammation |
BRPI0407335A (pt) * | 2003-02-07 | 2006-01-10 | Warner Lambert Co | Agentes antibacterianos |
TW200510356A (en) * | 2003-08-01 | 2005-03-16 | Takeda Chemical Industries Ltd | Benzoxaepine compounds |
US20050239767A1 (en) | 2003-10-28 | 2005-10-27 | Chan Michael K | Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands |
DE602005023730D1 (de) * | 2004-07-01 | 2010-11-04 | Merck Sharp & Dohme | Inhibitoren von mitotischem kinesin |
MX2007004051A (es) | 2004-10-07 | 2007-05-24 | Boehringer Ingelheim Int | Pi3-quinasas. |
EA019983B1 (ru) | 2005-10-07 | 2014-07-30 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
US20070238718A1 (en) * | 2006-04-06 | 2007-10-11 | Matthias Grauert | Thiazolyl-dihydro-indazole |
US20070238746A1 (en) * | 2006-04-06 | 2007-10-11 | Trixi Brandl | Thiazolyl-dihydro-chinazoline |
GB0610866D0 (en) * | 2006-06-02 | 2006-07-12 | Hammersmith Imanet Ltd | Novel in vivo imaging compounds |
WO2008014483A1 (en) * | 2006-07-28 | 2008-01-31 | Alcan Packaging Flexible France | Coextruded film with polylactic acid (pla) and ethylene vinyl acetate (eva) |
ES2614931T3 (es) | 2006-08-04 | 2017-06-02 | Beth Israel Deaconess Medical Center | Inhibidores de la piruvato cinasa y métodos de tratamiento de enfermedad |
US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
MX2009007050A (es) * | 2006-12-29 | 2009-09-23 | Abbott Gmbh & Co Kg | Compuestos de carboxamida y su uso como inhibidores de calpaina. |
AU2008302703B2 (en) | 2007-09-19 | 2013-11-07 | The Regents Of The University Of California | Positron emission tomography probes for imaging immune activation and selected cancers |
TWI443102B (zh) | 2008-03-31 | 2014-07-01 | Genentech Inc | 苯并哌喃及苯并氧呯pi3k抑制劑化合物及其使用方法 |
EP2350084B1 (en) * | 2008-10-17 | 2015-06-24 | Boehringer Ingelheim International GmbH | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor |
JP5546636B2 (ja) * | 2009-09-28 | 2014-07-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンゾキセピンpi3k阻害剤化合物及び使用方法 |
KR101428346B1 (ko) * | 2009-09-28 | 2014-08-07 | 에프. 호프만-라 로슈 아게 | 벤즈옥사제핀 pi3k 억제 화합물 및 사용 방법 |
-
2010
- 2010-09-27 KR KR1020127010974A patent/KR101428346B1/ko active IP Right Review Request
- 2010-09-27 ES ES13193562T patent/ES2570569T3/es active Active
- 2010-09-27 EP EP13193562.9A patent/EP2711368B1/en active Active
- 2010-09-27 SG SG10201405049RA patent/SG10201405049RA/en unknown
- 2010-09-27 RS RS20140060A patent/RS53164B/en unknown
- 2010-09-27 AU AU2010299816A patent/AU2010299816C1/en active Active
- 2010-09-27 CA CA2772691A patent/CA2772691C/en active Active
- 2010-09-27 WO PCT/EP2010/064208 patent/WO2011036280A1/en active Application Filing
- 2010-09-27 MY MYPI2015002473A patent/MY184074A/en unknown
- 2010-09-27 MX MX2012003591A patent/MX2012003591A/es active IP Right Grant
- 2010-09-27 EP EP10757213.3A patent/EP2483278B1/en active Active
- 2010-09-27 SI SI201030536T patent/SI2483278T1/sl unknown
- 2010-09-27 DK DK10757213.3T patent/DK2483278T3/da active
- 2010-09-27 MY MYPI2012000823A patent/MY160064A/en unknown
- 2010-09-27 TW TW099132661A patent/TWI423980B/zh active
- 2010-09-27 CN CN201080053938.XA patent/CN102762576B/zh active Active
- 2010-09-27 NZ NZ597833A patent/NZ597833A/en unknown
- 2010-09-27 JP JP2012530282A patent/JP5540101B2/ja active Active
- 2010-09-27 PT PT107572133T patent/PT2483278E/pt unknown
- 2010-09-27 RU RU2012117398/04A patent/RU2600927C2/ru active
- 2010-09-27 PE PE2012000390A patent/PE20121025A1/es active IP Right Grant
- 2010-09-27 CN CN201510043641.XA patent/CN104744491B/zh active Active
- 2010-09-27 AR ARP100103491A patent/AR078187A1/es unknown
- 2010-09-27 RU RU2016105810A patent/RU2654068C1/ru active
- 2010-09-27 ES ES10757213.3T patent/ES2444779T3/es active Active
- 2010-09-27 EP EP20140190276 patent/EP2845592A1/en not_active Withdrawn
- 2010-09-27 PL PL10757213T patent/PL2483278T3/pl unknown
- 2010-09-27 US US12/890,812 patent/US8242104B2/en active Active
- 2010-09-27 BR BR112012006807-5A patent/BR112012006807A2/pt not_active Application Discontinuation
-
2012
- 2012-01-10 CO CO12002995A patent/CO6491026A2/es active IP Right Grant
- 2012-01-16 IL IL217558A patent/IL217558A/en active IP Right Grant
- 2012-02-15 MA MA34637A patent/MA33531B1/fr unknown
- 2012-03-13 CR CR20120121A patent/CR20120121A/es unknown
- 2012-03-26 ZA ZA2012/02199A patent/ZA201202199B/en unknown
- 2012-03-27 CL CL2012000754A patent/CL2012000754A1/es unknown
- 2012-03-28 EC ECSP12011755 patent/ECSP12011755A/es unknown
- 2012-05-22 US US13/477,587 patent/US8343955B2/en active Active
- 2012-11-20 US US13/681,763 patent/US8586574B2/en active Active
-
2013
- 2013-02-07 HK HK13101739.9A patent/HK1174629A1/xx unknown
- 2013-02-07 HK HK15112815.1A patent/HK1211929A1/xx unknown
- 2013-10-07 US US14/047,206 patent/US8785626B2/en active Active
- 2013-11-01 JP JP2013228826A patent/JP5625101B2/ja active Active
-
2014
- 2014-03-12 HR HRP20140229AT patent/HRP20140229T1/hr unknown
- 2014-06-05 US US14/297,142 patent/US9198918B2/en active Active
-
2015
- 2015-05-28 IL IL239081A patent/IL239081B/en active IP Right Grant
- 2015-11-03 US US14/930,929 patent/US9546178B2/en active Active
-
2016
- 2016-12-05 US US15/368,937 patent/US9670228B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20120121A (es) | Compuestos de benzoxazepina como inhibidores de la pi3k y métodos de uso | |
CY1119345T1 (el) | Μακροκυκλικες ενωσεις ως αναστολεις κινασης trk | |
CR20120641A (es) | Compuestos macrocìclicos como inhibidores de quinasa trk | |
CR20120348A (es) | Nuevos compuestos tricíclicos | |
CR20120295A (es) | Triazolopiridinas | |
CR20150018A (es) | Inhibidores macrocíclicos de virus flaviviridae | |
CR20120297A (es) | Espironucleósidos uracílicos oxetánicos | |
ECSP12011581A (es) | Inhibidores de bace | |
CR20120417A (es) | Inhibidores de virus flaviviridae | |
UY34300A (es) | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit | |
CR20130118A (es) | DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC | |
UY34051A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
UY32292A (es) | Agonistas de s1p1 y métodos de preparación y uso | |
CR20140180A (es) | Inhibidores macrocíclicos de serina proteasas de hepatitis c | |
ECSP14027269A (es) | Picolinamidas macrocíclicas como fungicidas | |
NI201200020A (es) | Derivados de n1 - sulfonil - 5 - fluoropirimidinona | |
CR20130045A (es) | Compuestos terapéuticos | |
UY34301A (es) | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit | |
CR20120565A (es) | Indoles | |
UY34092A (es) | Nuevos compuestos como inhibidores de jak | |
CR20120635A (es) | Compuestos heterocìclicos de nitrògeno ùtiles como inhibidores de pde10 | |
CR20120158A (es) | Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso. | |
CR20130001A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
CR11373A (es) | COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA | |
DK2448938T3 (da) | Pyrimidinoner som pi3k-inhibitorer |